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A common property of sequence-selective DNA-binding drugs lies in their ability to induce an enhanced DNase I cleav- 
age in regions surrounding their binding sites. A hypothetical model to explain the enhancements induced by drug binding 
to the minor-groove of DNA is presented. It involves the participation of three different single models: a mass action 
effect produced by the enzyme redistribution after drug binding; changes in the minor groove width size; and interactions 
between the enzyme and the drug, so increasing the cleavage in places located close to the binding site. The model is 
tested by using statistical data analysisThe hypothetical model might explain the experimental results better than any 
of the single models alone, but these models also appear to render significant results. 
DNA-drug binding; Netropsin; Footprinting; DNase I cleavage nhancement 
1. INTRODUCTION 
Footprinting is a technique widely used in the 
analysis of sequence specificity of drugs which bind 
to DNA. The experimental approach is based on 
the ability of a DNA-bound ligand to protect its 
binding site(s) from enzymatic (or chemical) 
cleavage. Footprinting experiments have been 
employed to locate the binding sites for several 
drugs on different DNA fragments ([l-9] and 
references therein). Moreover it is also evident that 
the rate of cleavage at certain bonds is strongly 
enhanced relative to that in the control [l-9]. 
Although DNase I is not the only cleaving agent 
available, this nuclease appears to have several pro- 
perties that recommend it as an accurate foot- 
printing tool [3,6,10-121. Its mechanism of binding 
to and cutting DNA is well established [10,11,13]. 
Because after drug-binding several DNA regions 
are protected from DNase I cleavage, it could be 
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suggested that the enhancements in DNA cleavage 
are due to the restricted linear diffusion of the en- 
zyme on DNA, since the binding sites are blocked 
by the drug molecule. This situation (see fig.1) is 
considered a mass action effect that should provide 
us with a footprint where the non-protected DNA 
bonds would become equally enhanced. However, 
the analysis of published footprinting patterns 
[l-9] shows that this situation is not apparently 
observed, since in several cases, a clear enhance- 
ment appears in some of the DNA bonds, while 
others remain as in the original control lanes [l-9]. 
Two other theories can be put forward to explain 
the presence of DNA cleavage enhancements: (i) 
we can suppose that the enzyme exhibits some af- 
finity toward the drug molecule which is already 
bound to DNA, thus it would cut more effectively 
at sequences close to the binding sites [ 14,151. (ii) A 
different model would suggest hat the enhanced 
digestion may occur due to a conformational 
change in DNA brought about by the sequence- 
selective binding of drugs to the polynucleotide 
WW. 
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A common feature of sequence-selective binding 
drugs that intercalate between DNA base-pairs is 
the ability to unwind the’ DNA, so a more or less 
pronounced degree of unwinding [ 161 may produce 
the effect of opening up the grooves at neighbour- 
ing sequences [3,17]. It is noteworthy that some se- 
quences appear to be more affected than others. 
Diethylpyrocarbonate (DEPC)-mediated DNA 
strand cleavage in the presence of different mono- 
and %s-intercalators confirms the ability of some 
compounds to alter the DNA structure in a 
sequence-dependent manner [9,18-221. The altered 
structures can be observed either proximal or distal 
to the drug-binding sites [ 18,19,21], asituation that 
is consistent with drug-induced structural changes 
in DNA 1221. 
We should query if these results agree with an 
enzyme-distribution mechanism. Although both 
situations could exist together, it is to be noted that 
mass action effects alone might not explain the 
general levels of enhancements observed in foot- 
printing experiments using intercalating drugs 
[3-51. The second model requires the enzyme to ex- 
hibit some affinity for the drug molecule, being at- 
tracted to the bound ligand, so that it would cut 
more rapidly at sequences close to the binding sites. 
In general, this situation seems quite unlikely 
because the conformation of some drugs is such as 
to present few donor-acceptor groups for binding 
to the enzyme [3,16]. 
could explain the increment in cutting rates at 
several bonds both proximal and distal to the drug- 
binding sites [4,6,8], this simple model has a 
serious handicap since the minor groove binding 
ligands only produce relatively small changes in the 
structure of DNA [24-261. Enhancements have 
been suggested to arise from a drug-induced 
redistribution of the enzyme 114,151, with higher 
enhancement values for sites adjacent to binding 
sites, but this proposal does not explain the 
enhancements which are not in the vicinity of a 
binding site [6,8]. Data about whether the drugs 
that bound to DNA also bind to DNase I are scarce 
[3,12,14]. As a matter of fact, the drug-enzyme in- 
teraction is supposed to be different in the presence 
from that in the absence of DNA, since some of the 
potential drug-enzyme binding sites are involved in 
DNA-drug interactions. In spite of this, netropsin 
molecules bound to DNA could still form hy- 
drogen bonds to the enzyme through parts of the 
molecule which do not appear to be involved in 
hydrogen bonding to DNA [25]. 
HYPOTHETICAL FOOTPRINTING PATTERN 
MODELS FOR DNAase I CLEAVAGE ENHANCEMENTS 
A B G 
2. THE ORIGIN OF THE ABILITY OF 
MINORGROOVE BINDING DRUGS TO 
INDUCE ENHANCED RATES OF 
DNase I DIGESTION 
While for ligands that intercalate between DNA 
base-pairs the enhanced cleavage patterns appear 
to be mostly due to a conformational change in 
DNA, the situation with the minor-groove binding 
drugs remains less clear [14,15]. 
l enzyme 
In this article, I present a model to explain the 
DNase I cleavage enhancements after binding of 
drugs to the minor-groove of DNA. The hypo- 
thetical model, that will be tested using linear 
regression methods 1231, considers that the 
enhancements observed in the footprinting ex- 
periments [1,6-8,141 are produced by the combined 
action of the three models described above. 
Fig. 1. Illustration of hypothetical footprinting patterns pro- 
duced by DNase I cleavage of drug-DNA complexes in three dif- 
ferent situations. Sketchily, the figure displays both the cleavage 
model and the patterns that it should generate. (Model A) Mass 
action model. After drug binding the enzyme cleavage is 
enhanced at places which are not binding sites. (Model B) The 
nuclease digestion is enhanced at places close to the drug- 
binding sites. There is a drug-enzyme interaction. (Model C) 
After drug binding the DNA molecule undergoes a structural 
change that makes it more susceptible to the enzyme in several 
Although changes in the minor-groove width places both proximal and distal to the drug-binding sites. 
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GATATGATGCGCCCCGCTTCCCGATAAGGGAGCAGGCCAGTAAAAAG 
0 90 a 100 0 110 0 120 0 130 
Fig.2. A map of differential cleavage values (logarithmic scale) generated to simulate the hypothetical models A (v); B (m); and C (O), 
described in fig. 1. The differential cleavage values were calculated with respect o the tyrT DNA fragments (bonds 86 to 13 1), thus cor- 
recting them for the characteristic DNase I cutting behaviour [ 10,111. 
3. TESTING THE MODEL: A SIMULATION 
APPROACH 
Footprinting results obtained on the binding of 
netropsin to the tyrT DNA fragment [6] were com- 
pared with those theoretically generated using the 
following approach: three different digestion pat- 
terns, related with panels A, B and C in fig. 1, were 
created. A hypothetical DNase I digestion was 
simulated on a sequence-averaged DNA fragment. 
For purposes of comparison with the experimental 
results [6], the fragment was chosen to contain two 
netropsin-binding sites, which were similar in size 
and location to those found experimentally in the 
tyrT DNA between nucleotides 86 and 132 (see 
fig.3). A randomly selected integer number was 
used to represent theoretically a radioactively 
labelled DNA, i.e. the total quantity of radioactivi- 
ty of the DNA fragment. To simulate the DNase I 
cleavage the integer was divided between the 46 
bonds (i.e. the number of bonds between 
nucleotides 86 to 132), taking care to simulate the 
drug-binding sites with a small integer. The 
numerical quantities that were not used to repre- 
sent the cleavage at protected sites were then re- 
allocated to the drug-free bonds in order to 
simulate the enhancements. This was performed 
either randomly (model A in fig.1); accumulating 
the amounts in bonds close to the binding sites 
(model B); or in bonds located at intermediate 
places between drug-binding regions (model C), 
thus simulating any one of the three hypotheses 
described above (see fig.1). Data from the 
computer-simulated experiment are presented in 
the form of ln(&&ln(&~trOl) (fig.2) which 
represents the differential cleavage at each bond 
relative to that in the control (DNase I cutting in 
the absence of drug) [3-B]. The results are shown 
2 
i 
GATATGATGCGCCCCGCTTCCCGATAAGGGAGCAGGCCAGTAAAAAG 
l 90 l 100 a 110 0 120 l 130 
Fig.3. Plots of differential cleavage representing the effects of netropsin (0), and the hypothetical values generated by linear regression 
methods from models A, B and C (0) described in figs 1 and 2. Experimental data taken from (61. 
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on a logarithmic scale for convenience of plotting. 
Positive values indicate enhancements, negative 
values blockage. 
A statistical data analysis using linear regression 
methods [23] was undertaken to evaluate the ade- 
quacy of each model, taking the theoretically 
predicted radioactivity values as the independent 
variable and the experimental results as dependent 
variable [6]. The study was performed by using a 
GW-Basic computer program developed by the 
author from mathematical algorithms reported in 
[27]. All calculations were carried out on an 
Amstrad PC-1512SD computer. Fig.3 shows a 
comparison between an experimental cleavage plot 
[6] and a plot calculated for the hypothetical 
model. 
4. DISCUSSION 
The analysis of all the hypothetical model shows 
(table 1 and fig.3) that about 70% of the DNase I 
cleavage enhancements could be produced by a 
combined action of the three simple models in figs 
1 and 2 (?(A + B + C) = 0.7096), but also for any 
of the single models alone (A, B or C in fig.1 and 
table 1). It is to be noted that the variance explain- 
ed by the different models is similar in all the cases 
displayed in table 1. The hypothesis of a triple 
(combined) effect (mass action, DNA conforma- 
tional change, and enzyme-drug interaction) can- 
not explain all the observed enhancements. The 
same could be said about any of the simple models. 
Nevertheless, certain improvement of the correla- 
tion coefficient appears when a multivariate effect 
is considered (see table 1). 
Let us consider how the three effects can act 
together, since we can barely distinguish between 
them. The mass action effect is independent of the 
DNA sequence and is due to the linear redistribu- 
tion of the enzyme after drug binding. It reflects an 
equal distribution of DNase I molecules which are 
unable to cleave the drug-protected regions. It is in- 
ferred that a mass action effect will always be pre- 
sent. Although changes in DNA structure do not 
appear to be as spectacular as with intercalators 
[3,16,19] they still exist as shown by the over- 
winding effect of netropsin [24] and the ability of 
the drugs to change the minor-groove size [25,26]. 
DNase I cleavage of double helix DNA involves the 
binding of the enzyme to an exposed minor groove 
[13]. It is possible, therefore, that the nuclease may 
interact with netropsin molecules which are located 
in the AT-rich minor-groove [6,14,25,26]. 
Table 1 shows that the multiple action model is 
statistically significant. Nevertheless, it cannot ex- 
plain all the experimental results [6]. Probably, 
there is an effect of flanking sequences. The 
hypothetical models used in the simulated com- 
putation were built assuming an averaged DNA se- 
quence, except for the netropsin-binding sites 
(A+T rich regions at least four base-pairs long 
[1,6]), but in the tyrT DNA fragment - or indeed 
any natural DNA - the sequences flanking the 
binding sites are more or less different, thus affec- 
ting DNase I cleavage either in the presence of 
ligands [ 13,171 or their absence [111. For example, 
in fig.3 the differential cleavage plots are clearly 
different in the region between bonds 97 and 107. 
This is a pyrimidine-rich region (10 pyrimidines 
among 11 bases, against 19 among 46 in the entire 
Table 1 
Comparison between data obtained in a netropsin DNA-interaction by simulation 
processes and experimental results 
Simple correlation Multiple correlation 
Model I ? t Model r 2 F 
A 0.8377 0.7017 10.172 A+B 0.8423 0.7095 52.514 
B 0.8422 0.7093 10.361 A+C 0.8391 0.7040 51.139 
C 0.8356 0.6982 10.089 B+C 0.8424 0.7096 52.524 
A+B+C 0.8424 0.7096 34.214 
(n=46; p< 10-4) (n =46; p< 10-4) 
‘Model’ refers to different theoretical models for DNase I cleavage nhancements after 
drug binding, as described in figs 1 and 2. r is the Pearson’s correlation coefficient and ? 
the variance explained by the model. F is the Snedecor’s F-value and t the Students-t value 
11 
Volume 25 1, number 1,2 FEBS LETTERS July 1989 
fragment). A peculiar conformation of this DNA 
region could explain its different behaviour, either 
by changes in DNA conformation after drug 
binding and/or by affecting the interaction be- 
tween the bound drug and the enzyme. In fact, 
poly(dA) - poly(dT) or poly(dG) + poly(dC), which 
contain a pyrimidine polynucleotide strand, are 
known to be structurally abnormal and essentially 
straight [28], so they are, for example, able to resist 
reconstitution into nucleosomes [29-301. The 
Levene and Crothers model for DNA bending [31] 
proposes that poly(A) runs adopt a non-B confor- 
mation and there is a marked change in direction of 
the helix axis at the junction between B and non-B 
DNA regions. Furthermore, DNase I covers at 
least four base pairs at the 5 ’ - and six base pairs at 
the 3’-side [ 131, so the bulk of DNase I can 
produce a different pattern on either side of the 
binding region which cannot be easily introduced 
in a simulated model. 
The footprinting technique allows evaluation of 
drug-binding constants [12,14,15]. The presence of 
DNase I cleavage enhancements away from the 
binding site needs to be considered in determining 
binding constants from footprinting data [ 14,151. 
The correction of this effect during the quantitative 
treatment of data has assumed [15] that the 
enhancement pattern arises from a redistribution 
of DNase I molecules. The hypothetical model 
presented in this article shows that although this ef- 
fect is significant it would be desirable to take into 
account that DNA structural changes are also in- 
volved in the enhancement patterns. 
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